Drug General Information (ID: DDIK6FP19X)
Drug Name			Lenalidomide		Drug Info		Simvastatin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Statins/Antihyperlipidemic Agents
Structure

Mechanism of Lenalidomide-Simvastatin Interaction (Severity Level: Major)
Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Lenalidomide				Simvastatin
Mechanism		Rhabdomyolysis				Rhabdomyolysis
Key Mechanism Factor 1
		Factor Name		Adverse reactions
		Factor Description		An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
Mechanism Description		Increased risk of adverse reactions by the combination of Lenalidomide and Simvastatin

Recommended Action
Management		European product labeling recommends caution and increased clinical and biological monitoring if lenalidomide is used in combination with statins, especially during the first several weeks of treatment. All patients treated with statins should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports."
3	EMA. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) "Revlimid."